HealthMore in Health→
Phase 2 trial reports strong signal for FGFR inhibitor in SDH-deficient GIST
A multicenter phase 2 trial found partial responses in 10 of 24 patients with advanced SDH-deficient GIST, with median progression-free survival reaching 31 months.
Key Takeaways
- Ten of 24 patients had partial responses in the phase 2 trial.
- Median progression-free survival reached 31.0 months.
DE
DT Editorial Team··via nature.com